Cargando…
Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with othe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896132/ https://www.ncbi.nlm.nih.gov/pubmed/29642900 http://dx.doi.org/10.1186/s12967-018-1471-1 |
_version_ | 1783313782694477824 |
---|---|
author | Achkar, Iman W. Abdulrahman, Nabeel Al-Sulaiti, Hend Joseph, Jensa Mariam Uddin, Shahab Mraiche, Fatima |
author_facet | Achkar, Iman W. Abdulrahman, Nabeel Al-Sulaiti, Hend Joseph, Jensa Mariam Uddin, Shahab Mraiche, Fatima |
author_sort | Achkar, Iman W. |
collection | PubMed |
description | Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin. |
format | Online Article Text |
id | pubmed-5896132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58961322018-04-20 Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway Achkar, Iman W. Abdulrahman, Nabeel Al-Sulaiti, Hend Joseph, Jensa Mariam Uddin, Shahab Mraiche, Fatima J Transl Med Review Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin. BioMed Central 2018-04-11 /pmc/articles/PMC5896132/ /pubmed/29642900 http://dx.doi.org/10.1186/s12967-018-1471-1 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Achkar, Iman W. Abdulrahman, Nabeel Al-Sulaiti, Hend Joseph, Jensa Mariam Uddin, Shahab Mraiche, Fatima Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
title | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
title_full | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
title_fullStr | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
title_full_unstemmed | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
title_short | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
title_sort | cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896132/ https://www.ncbi.nlm.nih.gov/pubmed/29642900 http://dx.doi.org/10.1186/s12967-018-1471-1 |
work_keys_str_mv | AT achkarimanw cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway AT abdulrahmannabeel cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway AT alsulaitihend cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway AT josephjensamariam cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway AT uddinshahab cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway AT mraichefatima cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway |